NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Analysis of revenues and R&D prospects for those eye drugs - you explore potentials
What's the future for treating disorders of the retina? Visiongain's updated report forecasts those pharma revenues. There you find outlooks for sales growth in that industry. You also explore trends, technologies, therapies, and opportunities.
That analysis gives you predictions of revenues to 2024 at overall world market, submarket, product, and national level. Avoid falling behind in data, then, missing business or losing influence. So find what's happening for those ocular medicines. Discover how you can gain.
Read on to explore those products and see what their future could be worth.
Forecasts and other information to benefit your research and analyses
Besides revenue forecasting to 2024, our new work shows historical data, growth rates, and market shares. There you find original analysis. Explore research and development (R&D) too. You also get 36 tables, 38 charts, and two interviews with other authorities.
Anyhow, the future appears promising for companies treating those eye disorders.
Ophthalmic technology - find growth opportunities and how to help your work
That new study lets you investigate the most promising and lucrative treatments for neovascularisation and other rear eye ailments. You explore technologies and applications.
There you hear what's happening and discover where the money lies. So benefit your research, analyses, and decisions. Stay ahead, then, without missing out. See, too, how you could extend your influence.
The following sections explain what you get in our new investigation.
Forecasting the world market and segments for medicines treating retinal disorders
What're the secrets of that technology's progress? What's its potential? Find in our report overall world revenue to 2024 for retinal medicines.
Also explore individual revenue predictions to 2024 for four therapeutic submarkets at world level:
• Wet age-related macular degeneration (AMD)
• Dry AMD
• Diabetic retinopathy (DR)
• Other retinal diseases.
Where lie the best prospects? There you assess outlooks for revenue expansion, seeing where you can gain.
That work also covers geographic atrophy (GA) and diabetic macular oedema/edema (DME), as well as proliferative and non-proliferative diabetic retinopathy.
You find sales predictions by product, too, hearing how they can succeed.
Predictions of leading products' sales
How will individual drugs perform from 2013 to 2024 at world level? Our study forecasts revenues of three established brands:• Lucentis• Eylea• Avastin.
There you discover how high sales can go, finding agents and years with highest predicted revenues. Also examine competition. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.
Single and combination treatments matter. Our report explains. That work also shows you geographical predictions.
Healthcare in national markets - what outlooks for retinal medical sales?
Advances in biotechnology and pharmaceuticals expand use of drugs to treat back-of-eye impairments and vision loss. You gain feel for those technologies' revenue prospects.
Our work shows you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.
There you find countries with highest revenues and potential growth. You explore outlooks for treating ocular problems, serving needs. Assess opportunity. Discover, then, how you and your organisation can gain.
You also examine developments leading to novel treatments.
Developing products - discover trends, innovations, and progress
You also investigate R&D, appraising technological and commercial possibilities.
So assess research and developments to slow vision loss and restore sight. Our report discusses these advances and others:• Combination therapies, inc. neovascularisation cascade blockers• Blocking pericyte recruitment• Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis)• Monoclonal antibodies (mAbs), mAb fragments, DARPins (designed ankyrin repeat proteins), and visual cycle modulators• Anti-inflammatory mechanisms (inc. corticosteroids).
And agents including these:
• Complement factor inhibition and serotonin modifiers
• Anti-integrin oligopeptide treatment
• Oligonucleotides and siRNA therapy
• Angiotensin receptor blockers and converting enzyme inhibitors
• Regenerative medicine, neural stem cells, cellular and gene therapies.
R&D there holds strength, variety, and promise. See what's possible for big pharma companies and specialists in biological drugs (biologics) and other biotechnologies.
You explore progress, then, assessing that industry's participants and their futures.
Companies and overall 2017 market value - what predicted revenues?
Our analyses predict the world market for retinal drugs will reach $9.8bn in 2017. It will rise with double-digit growth during our forecasted period. You find how high sales can go.
You also see what organisations hold most potential. Examine companies including these:• Novartis• Roche• Regeneron• Bayer• Neurotech Pharmaceuticals• Allergan.
You find 135 organisations mentioned. Also read two interviews with authorities on retinal conditions. Discover, then, what that field does, says, and thinks. Now you can stay ahead.
Ways Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024 helps you
In particular, our new investigation gives you this knowledge:
• Revenues to 2024 for retinal medications at overall world level, 4 submarkets, and 3 top products - assess prospects for investments, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia -investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies, and new entrants - examine portfolios, results, R&D, and outlooks for success.
Information found nowhere else, letting you appraise medicines in ophthalmics
That new report gives independent analysis. There you receive competitive intelligence found only in our work, finding where the money lies. Explore progress and possibilities.
With that data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find how you could save time and effort there, also benefiting your authority.
1. Executive Summary
1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
2. Overview of the AMD and Other Retinal Diseases Market, 2014-2024
2.1 Market to Make Rapid Strides to 2024
2.2 Lucentis Still Holds Over 70% of the Total Market
2.2.1 Novartis the Leading Presence in the Market
2.3 Which are the Most Significant Disease Areas for the Market?
2.3.1 Nearly 200 Million People with AMD?
2.3.2 Over 100 Million with DR
2.3.3 First RVO Estimates Suggest Patient Population of 16 Million
2.3.4 Wet AMD Still the Main Source of Revenues in the Market
2.4 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
2.5 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
2.6 DR: Coming Into Clinical Focus, with DME the Main Target
2.7 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
2.8 Projections for All Segments, 2014-2024
3. Approved Products in the AMD and Other Retinal Diseases Market, 2014-2024
3.1 Will the Current Products Dominate the Market Through 2024?
3.2 Lucentis: The Market Leader, But For How Long?
3.2.1 Shadow of Avastin Still Hangs Over Lucentis
3.2.2 CATT Study Results: Clinical Differences Still Have Yet to Emerge
3.2.3 Eylea: The Bigger Threat to Lucentis?
3.2.4 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
3.2.5 Improving Cost and Compliance for Lucentis
3.2.6 Will Loss of Physician Goodwill Harm Lucentis' Growth?
3.2.7 Lucentis Revenue Forecast 2014-2024
3.3 Eylea: Pretender to the Throne?
3.3.1 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
3.3.2 First Wave of Eylea's Expansion Finally Beginning to Break?
3.3.3 Into DME and Other New Indications
3.3.4 Zaltrap Targeting Solid Tumour Markets
3.3.5 How Far Can Eylea's Momentum Carry It?
3.3.6 Eylea Revenue Forecast 2014-2024
3.4 Avastin: No Formal wAMD Approval But Still the Most-Used Product
3.4.1 Judicial Review Averted in the UK by Price Adjustment
3.4.2 Multiple Attempts to Block Off-Label Avastin Since 2007
3.4.3 Roche and Novartis Challenge CATT's Headline Conclusions
3.4.4 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
3.4.5 Will Anything Dislodge Avastin from its Central Position?
3.4.6 Market Forecast for Avastin, 2014-2024
4. Wet AMD Segment, 2014-2024
4.1 Eylea The Segment's Biggest Short-Term Driver
4.2 R&D Pipeline for wAMD: The Leading Candidates
4.3 Fovista (Ophthotech Corporation): The Next Big Thing?
4.3.1 Three Phase 3 Trials to Confirm Fovista's Outstanding Phase 2 Results
4.3.2 Ophthotech Goes Public to Fund Phase 3 Effort
4.3.3 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
4.3.4 The Move Toward Combination Therapies
4.4 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
4.4.1 Preclinical DARPin Hits VEGF and PDGF
4.4.2 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
4.4.3 Other Growth Factor Targets in the Pipeline
4.4.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P MAb
4.5 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
4.5.1 A Chinese Competitor: Where Will Conbercept Fit In?
4.5.2 Binding Affinity Comparable to Eylea
4.6 Do We Need New Anti-VEGFR Agents or Delivery Systems?
4.6.1 AGN-150998 DARPin (Allergan): Novel Protein With Extended Half-Life
4.6.2 ESBA 1008 (Alcon): Single-Chain mAb Fragment
4.6.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
4.6.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
4.6.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
4.6.6 Iontophoretic Delivery: Eyegate Pharmaceuticals Leading the Way
4.7 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
4.7.1 IBI-20089 (Icon Bioscience): Steroid Gel for Slow Release
4.7.2 OT-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
4.8 Other Targets Under Investigation in wAMD Drug Development
4.8.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
4.8.2 Pazopanib and TG100801: Two Eyedrop Kinase Inhibitors Drop Out of the Running
4.8.3 First Ophthalmic Complement Factor Inhibitor, AL-78898A, Misses Primary Endpoint
4.8.4 Factor C5: A More Promising Target Addressed by LFG316 (Novartis)
4.8.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
4.8.6 ALG-1001 (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
4.8.7 Ocriplasmin (Thrombogenics): Can Pharmacologic Vitreolysis Help wAMD Patients?
4.8.8 Novel Anti-Angiogenic Treatments in Development
4.8.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
4.8.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
4.9 Regenerative Medicine Approaches
4.9.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use Alongside Lucentis
4.9.2 AVA-101(Avalanche Biotechnologies): Ocular BioFactory for wAMD
4.9.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
5. Dry AMD Segment, 2014-2024
5.1 Dry AMD Segment to Emerge in the Forecast Period
5.2 Who Will Achieve the Big Breakthrough in Dry AMD?
5.3 MC-1101 (MacuCLEAR): Leading the Pack?
5.3.1 Increasing Choroidal Blood Flow with Repurposed Product
5.3.2 Novel Endpoints in Phase 3 Study
5.3.3 Can MacuCLEAR Make It?
5.4 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
5.4.1 Data Expected in July 2016
5.4.2 Other Visual Cycle Modulators
5.5 Lampalizumab (Roche): The Big News of ARVO 2013
5.5.1 MAHALO Study Indicates GA Progression Slowed by Lampa
5.5.2 High Hopes for Complement Inhibition in Dry AMD
5.5.3 AL-78898A (Alcon): Still Under Investigation in Dry AMD
5.5.4 Soliris (Alexion): Out of the Running?
5.6 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
5.6.1 Medidur Fluocinolone Acetonide (Alimera Sciences): Insert in Phase 2
5.6.2 AGN208397 (Allergan): New Potent Steroid Expected to Be Trialled in Dry AMD
5.7 Neuroprotection: One of Modern Medicine's Holy Grails
5.7.1 Tandospirone (Alcon): No News On Serotonin 1A Agonist
5.7.2 NT501 (Neurotech): Some Promising Data in Dry AMD Studies
5.7.3 Brimonidine Tartrate (Allergan): Possible Efficacy with Longer Duration of Action
5.7.4 RN6G (Pfizer): Amyloid Beta-Binding MAb Still in Studies
5.7.5 VAR10200 (Varinel): A Preclinical Candidate to Watch
5.8 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
5.8.1 MA09-hRPE Cellular Therapy (Advanced Cell Technology): Signs of Efficacy in Landmark ESC Human Trial
5.8.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
5.8.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
5.8.4 Biotime: Stem Cell leader with Dry AMD Interests
5.8.5 First iPSC Trial in Japan in Dry AMD Patients
5.8.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
5.9 Other Treatments for Dry AMD
6. Diabetic Retinopathy Segment, 2014-2024
6.1 Segment to Grow in Importance as Diabetes Epidemic Continues
6.2 DR Options Grow with DME Addressed by New Agents
6.3 Lucentis: The Game Changer for DR?
6.3.1 New Anti-VEGF Additions
6.4 A New Hope? Optina (Ampio Pharmaceuticals)
6.4.1 Other Steroids in Development for DR
6.4.2 Iluvien (Alimera/pSivida): New Option in European Markets
6.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
6.4.4 Ozurdex (Allergan): Under Investigation in Several Indications
6.4.5 SK-0503 (Sanwa Kagaku Kenkyusho): Potential DME and BRVO Treatment
6.4.6 Cortiject (Novagali Pharma): Prodrug Candidate
6.5 Other Products in Development for DR
6.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
6.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
6.5.3 Choline Fenofibrate (Abbott): No New Development for Promising Drug
6.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
6.5.5 Darapladib (GlaxoSmithKline): Possible New Use for Atherosclerosis Drug
6.5.6 Bromfenac Ophthalmic Solution (ISTA Pharmaceuticals): New NSAID Option?
6.5.7 Ocriplasmin: Possibilities in DME?
7. Regional Market Breakdown, 2014-2024
7.1 Which Markets Hold the Most Revenue Growth Potential?
7.2 The US: Leading Market for Retinal Diseases
7.3 Japan: Strong Market Potential
7.4 EU5: Ageing Populations to Drive Market Growth
7.5 BRIC Nations: The Biggest Growth Driver for the Market
8. Qualitative Analysis, 2014-2024
8.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
8.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
8.3 Opportunities: New Markets and R&D Synergies
8.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
8.5 Social: Low Diagnosis, Low Compliance
8.6 Technological: Innovation for the Eye
8.7 Economic: Off-Label Treatment and Reimbursement Issues
8.8 Political: The Demography and Diabetes Challenges
9. Research Interviews from Our Survey
9.1 Interview with Dr Michael Stewart, Mayo Clinic
9.1.1 The Impact of Eylea, 2011-2012
9.1.2 The Comparative Dosing Schedules of Eylea and Lucentis
9.1.3 Patient Transitioning to Eylea: Salvage Switching
9.1.4 Avastin After the CATT Study
9.1.5 Prospects for Eylea in Other Indications and Combinations
9.1.6 Future Possibilities in Wet AMD Treatment
9.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
9.2.1 MC-1101: Identifying and Treating Chiou Syndrome
9.2.2 Preventing Dry AMD Progression
9.2.3 Treating the Root Cause of Dry AMD
9.2.4 Phase 3: Endpoints and Prospects for MC-1101
10. Report Conclusions
10.1 The Age of Lucentis: Nearing Its Conclusion?
10.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
10.3 Indications Outside Wet AMD to Gain in Importance
10.4 Dry AMD Market Has Huge Potential
10.5 Fovista Most Prominent Among the Pipeline Candidates
10.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
List of Tables
Table 1.1 Currency Exchange Rates
Table 2.1 AMD and Other Retinal Diseases Pharmaceutical Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 2.2 AMD and Other Retinal Diseases Pharmaceutical Market: Revenues ($m), AGR (%), CAGR (%), 2018-2024
Table 2.3 Market Breakdown by Product: Revenues ($m), Market Share (%), 2012
Table 2.4 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2012
Table 2.5 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2012
Table 2.6 Retinal Diseases Market Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 2.7 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2017
Table 2.8 Retinal Diseases Market Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 2.9 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2024
Table 3.1 Market Breakdown by Product: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 3.2 Market Breakdown by Product: Revenues ($m), Market Share (%), 2017
Table 3.3 Market Breakdown by Product: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 3.4 Market Breakdown by Product: Revenues ($m), Market Share (%), 2024
Table 3.5 Lucentis, Eylea and Avastin: Comparison of Characteristics
Table 3.6 Lucentis: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 3.7 Lucentis: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 3.8 Eylea: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 3.9 Eylea: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 3.10 Avastin: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 3.11 Avastin: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.1 Wet AMD Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 4.2 Wet AMD Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.3 Selected R&D Pipeline for wAMD, 2013
Table 5.1 Dry AMD Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 5.2 Dry AMD Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 5.3 Selected R&D Pipeline for Dry AMD, 2013
Table 6.1 DR Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 6.2 DR Segment: Revenues: ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 6.3 Selected R&D Pipeline for DR, 2013
Table 7.1 Regional Breakdown: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 7.2 Regional Breakdown: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 7.3 EU5 Breakdown: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 7.4 EU5 Breakdown: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 7.5 BRIC Nations Breakdown: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017
Table 7.6 BRIC Nations Breakdown: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024
List of Figures
Figure 2.1 AMD and Other Retinal Diseases Pharmaceutical Market: Revenues ($m), 2012-2024
Figure 2.2 Market Breakdown by Product Revenues ($m), Market Share (%), 2012
Figure 2.3 Market Breakdown by Company: Market Share (%), 2012
Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
Figure 2.6 Global Over-60s Population (m), as Proportion of Total (%), 2012-2024
Figure 2.7 Market Breakdown by Disease Segment: Revenues ($m), 2012
Figure 2.8 Wet AMD Disease Segment: Market Share (%), 2012
Figure 2.9 Dry AMD Disease Segment: Market Share (%), 2012
Figure 2.10 DR Disease Segment: Market Share (%), 2012
Figure 2.11 Other Retinal Diseases Segment: Market Share (%), 2012
Figure 2.12 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2017
Figure 2.13 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2024
Figure 2.14 Retinal Diseases Market Breakdown by Segment: Revenues ($m), 2012-2024
Figure 2.15 Retinal Diseases Market Breakdown by Segment: Revenues ($m), 2012, 2018 and 2024
Figure 3.1 Market Breakdown by Product: Revenues ($m), Market Share (%), 2017
Figure 3.2 Market Breakdown by Product: Revenues ($m), Market Share (%), 2024
Figure 3.3 Market Breakdown by Product: Revenues ($m), 2012-2024
Figure 3.4 Market Breakdown by Product: Revenues ($m), 2012, 2018 and 2024
Figure 3.5 Drivers and Restraints for Lucentis, 2013
Figure 3.6 Lucentis: Revenues ($m), 2012-2024
Figure 3.7 Drivers and Restraints for Eylea, 2013
Figure 3.8 Eylea: Revenues ($m), 2012-2024
Figure 3.9 Drivers and Restraints for Avastin, 2013
Figure 3.10 Avastin: Revenues ($m), 2012-2024
Figure 4.1 Wet AMD Segment: Revenues ($m), 2012-2024
Figure 5.1 Dry AMD Segment: Revenues ($m), 2012-2024
Figure 6.1 DR Segment: Revenues ($m), 2012-2024
Figure 7.1 Regional Breakdown: Revenues ($m), 2012-2024
Figure 7.2 Regional Breakdown: Revenues ($m), 2012, 2018 and 2024
Figure 7.3 US Market: Revenues ($m), 2012-2024
Figure 7.4 Japan: Revenues ($m), 2012-2024
Figure 7.5 EU5: Grouped Revenues ($m), 2012-2024
Figure 7.6 EU5 Breakdown: Revenues ($m), 2012-2024
Figure 7.7 EU5 Breakdown: Revenues ($m), 2012, 2018 and 2024
Figure 7.8 BRIC Nations: Grouped Revenues ($m), 2012-2024
Figure 7.9 BRIC Nations Breakdown: Revenues ($m), 2012-2024
Figure 7.10 BRIC Nations Breakdown: Revenues ($m), 2012, 2018 and 2024
Advanced Cell Technologies
American Academy of Ophthalmology
American Society of Retina Specialists
Applied Genetic Technologies
Association for Research in Vision and Ophthalmology (ARVO)
Bausch & Lomb
Bayer Yakuhin (Bayer subsidiary)
Casey Eye Institute at Oregon Health and Science University
Cell Cure Neurosciences
Chengdu Kanghong Biotech
ES Cell International
European Court of Justice
European Medicines Agency (EMEA/EMA)
Food and Drug Administration (US FDA)
General Medical Council (GMC, UK)
Human Genome Sciences
Innovations in Sight
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG, Germany) International Diabetes Foundation
Institute of Ocular Pharmacology
Kaplan Medical Center
Ludwig-Maximilians - University of Munich
Merck & Co.
National Eye Institute (NEI, US)
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
Numoda Capital Innovations
Oklahoma Medical Research Foundation
Österreichische Agentur für Gesundheit und Ernährungssicherheit (AGES, Austria)
Pele Nova Biotecnologica
Retina Macula Institute
Sanwa Kagaku Kenkyusho
Singapore Eye Research Institute
Singapore National Eye Centre
Stemedica Cell Technologies
Teva Pharmaceutical Industries
University of Kentucky College of Medicine
University of Kyoto
World Health Organization (WHO)
To order this report: Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024 http://www.reportlinker.com/p02006103/Macular-Degeneration-AMD-and-Other-Retinal-Diseases-World-Drug-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001